Home » Uncategorized (Page 180)
Category Archives: Uncategorized
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....FOR BLOG HOME CLICK HEREFlag and hits
ORGANIC SPECTROSCOPY
SUBSCRIBE
Subscribe in a reader
Enter your email address:
Delivered by FeedBurner
Subscribe to New Drug Approvals by Email
Recent Comments
 | shivkr2 on SPSR Excellence Award 2025 – S… |
 | Bonkasaurus on Infigratinib phosphate |
 | PALOVAROTENE | ORGAN… on Palovarotene |
| Pfizer just purchase… on Temanogrel | |
| Pfizer To Cash In On… on Temanogrel |
HOME REMEDIES FOR CHOLESTEROL
Home Remedies for Cholesterol: Onions contain high levels of quercetin, an important flavonoid that reduces cholesterol. high concentrations of the compound quercetin hinderS the oxidation process of LDL, or “bad,” cholesterol, which help prevent the negative effects of this type of cholesterol.
===> http://www.askveda.in/ – Ayurveda health-tips, home remedies & expert advice
Antibody lipid treatments enter final furlong
A tiny pain-free jab every two weeks could be the future of cholesterol-lowering for high-risk patients, according to clinical researchers gathered in Amsterdam for the European Society of Cardiology congress.
Eli Roth at the University of Cincinnati said that two companies are currently neck and neck in the race to bring the first PCSK9 antibody to market. Partners Sanofi and Regeneron may have the edge, with Phase III data on their fully human monoclonal antibody alirocumab slated to be presented before the end of the year, while the chief competition comes from Amgen with its antibody AMG 145, said Dr Roth. Both antibodies can be delivered via subcutaneous auto-injectors, which many patients say they prefer to taking daily pills, he added.
http://www.pharmatimes.com/Article/13-09-02/Antibody_lipid_treatments_enter_final_furlong.aspx
Alirocumab is a human monoclonal antibody designed for the treatment ofhypercholesterolemia.[1]
This drug was discovered by Regeneron Pharmaceuticals and is being co-developed by Regeron and Sanofi.
THERAPEUTIC CLAIM Treatment of hypercholesterolemia
CHEMICAL NAMES
1. Immunoglobulin G1, anti-(human neural apoptosis-regulated proteinase 1) (human
REGN727 heavy chain), disulfide with human REGN727 κ-chain, dimer
2. Immunoglobulin G1, anti-(human proprotein convertase subtilisin/kexin type 9
(EC=3.4.21.-, neural apoptosis-regulated convertase 1, proprotein convertase 9,
subtilisin/kexin-like protease PC9)); human monoclonal REGN727 des-448-
lysine(CH3-K107)-1 heavy chain (221-220′)-disulfide with human monoclonal
REGN727 light chain dimer (227-227”:230-230”)-bisdisulfide
MOLECULAR FORMULA C6472H9996N1736O2032S42
MOLECULAR WEIGHT 146.0 kDa
SPONSOR Regeneron Pharmaceuticals
CODE DESIGNATION REGN727, SAR236553
CAS REGISTRY NUMBER 1245916-14-6
DCGI asks Wockhardt, Ranbaxy to explain lapses
ALL ABOUT DRUGS BY DR ANTHONY MELVIN CRASTO, WORLD DRUG TRACKER HELPING MILLIONS, MILLION HITS ON GOOGLE……………………………………….
Stick insect leads antibiotic hunt, Norwich researchers say
The gut of the Giant Lime Green stick insect could hold the key to antibiotic resistance
A microbe in the gut of a stick insect could help scientists to unravel the puzzle of antibiotic resistance.
The Giant Lime Green stick insect, which feeds mainly on eucalyptus leaves, is being studied at the John Innes Centre (JIC) in Norwich.
In the laboratory it has shown resistance to toxins and infections it could never have encountered before.
This indicates a general mechanism at work and understanding this could lead to new drugs, JIC scientists believe.
Scientists at JIC are confident studying natural processes will reveal new antibiotics.
The pressure is on to make discoveries because every year more drugs are made ineffective by microbe resistance.
Ants carry antibiotic
Professor Tony Maxwell, head of biological chemistry, said: “We have discovered the microbe in the stick insect’s gut is resistant to toxins and infections…
View original post 390 more words
Hope In A Pill- A crop of small-molecule drugs in development could double the treatment options for people with multiple sclerosis in coming years
EMD Serono
Blueberries, not fruit juice, cut type-2 diabetes risk
http://www.bbc.co.uk/news/health-23880701
Eating more fruit, particularly blueberries, apples and grapes, is linked to a reduced risk of developing type-2 diabetes, suggests a study in the British Medical Journal.
Blueberries cut the risk by 26% compared with 2% for three servings of any whole fruit – but fruit juice did not appear to have the same effect.
The research looked at the diets of more than 187,000 people in the US.
But Diabetes UK said the results of the study should be treated with caution.
Researchers from the UK, US and Singapore used data from three large studies of nurses and health professionals in the US to examine the link between fruit consumption and the risk of contracting type-2 diabetes.
What is type-2 diabetes?
Diabetes is an incurable condition in which the body cannot control blood sugar levels, because of problems with the hormone insulin.
In type-2 diabetes, either the pancreas…
View original post 632 more words
GLIPTINS: BETTER APPROACH FOR TYPE 2 DIABETES
GLIPTINS: BETTER APPROACH FOR TYPE 2 DIABETES
Diabetes Mellitus is a metabolic disorder which results from defects in insulin secretion, insulin action, or both, further characterized by hyperglycemia, and causes long term damage and failure of various organs. It is estimated that 366 million people had Diabetes Mellitus in 2011; by 2030 this would have risen to 552 million. Many oral hypoglycaemic agents are…
read more: http://www.pharmatutor.org/articles/gliptins-better-approach-type-2-diabetes
Capecitabine Intermediate-cxpharma
Jiangsu Chengxin Pharmaceutical Co., Ltd with total area 60,000m2 and total invested amount of RMB 300 million, is a high-tech joint-stock enterprise established in 2012, located in Binjiang Pharm-Chem Industry Park, Qidong, the outstanding cultural city well known as the Rivers and Seas Pearl in Jiangsu Province, close to Chongming Island with merely one separated river. It takes around 1 hour by car from the manufacturing site to Shanghai, the Yangtze River Delta economic metropoli……More
http://www.cxpharma.com/en/about.asp?id=8
Dear sir,
We are just a manufacturer and very strong in the following intermediates:
Intermediates for Capecitabine:
2′,3′-Di-O-acetyl-5′-deoxy-5-fluorocytidine (CAS: 161599-46-8)
1,2,3-Triacetyl-5-deoxy-D-ribose (CAS: 62211-93-2)
Methyl-5-deoxy-2,3-O-isopropylidene-beta-D-ribofuranoside (CAS: 23202-81-5)
We have the dedicated workshop for Capecitabine intermediate. Our capacity is more than 20MT per month. Our company is complied with the requirement from EU GMP, US FDA and Chinese GMP. Just for your information.
If you are interested in any of above, please let me know.
Looking forward to your early reply.
Best regards,
Runya Wang(Ms) / Sales Department
Add: No.338 Shanghai Road, Binjiang Pharm-Chem
Industry Park, Qidong, Jiangsu, P.R.China 226221
Tel: 0086-513-86029596
Fax: 0086-513-86105399
Email: runya.wang@cxpharma.com
Web: www.cxpharma.com
http://www.cxpharma.com/en/home.asp in english
Roche reports positive Phase II results for experimental eye drug
Lampalizumab
Roche reports positive Phase II results for experimental eye drug
Lampalizumab, an experimental eye drug from Roche, has helped slow down the progression of an advanced form of age-related macular degeneration (AMD) in a Phase II study, the company announced this week.
READ ALL AT
SEE ALSO
Lampalizumab effective in Phase II clinical trial for macular degeneration
Roche’s new drug for age-related macular degeneration, lampalizumab, showed effective in slowing the progression of AMD in patients with advanced disease, shrinking the area of geographic atrophy by 20%. Read More >>
Lampalizumab (INN) is a humanized monoclonal antibody designed for the treatment of geographic atrophy secondary to age-related macular degeneration. It binds to CFD.[1][2]
This drug was developed by Genentech/Roche.
References
The U.S. Food and Drug Administration (FDA) has approved Mirvaso (brimonidine) topical gel for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older
brimonidine
Mirvaso
Generic Name: brimonidine
Date of Approval: August 23, 2013
Company: Galderma Laboratories, L.P.
Treatment for: Facial Erythema (Redness) of Rosacea
READ ALL AT
http://www.drugs.com/mirvaso.html
Brimonidine (bri-MOE-ni-deen, brand names Alphagan and Alphagan-P) is a drug used to treat open-angle glaucoma or ocular hypertension.
It acts via decreasing synthesis of aqueous humor, and increasing the amount that drains from the eye through uveoscleral outflow. As a treatment for glaucoma, it is usually given in eyedrop form.
Mechanism of action
Brimonidine is an α2 adrenergic agonist.
Alpha 2 agonists, through the activation of a G protein-coupled receptor, inhibit the activity of adenylate cyclase. This reduces cAMP and hence aqueous humour production by the ciliary body.
Peripheral alpha 2 agonist activity results in vasoconstriction of blood vessels (as opposed to central alpha 2 agonist activity that decreases sympathetic tone, as can be seen by the medication clonidine). This vasoconstriction may explain the acute reduction in aqueous humor flow. The increased uveoscleral outflow from prolonged use may be explained by increased prostaglandin release due to alpha adrenergic stimulation. This may lead to relaxed ciliary muscle and increased uveoscleral outflow.[1]
Clinical uses
Brimonidine is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is also the active ingredient of Combigan along with timolol maleate.
In 2013, the FDA approved topical application of brimonidine 0.33% (Mirvaso) for facial erythema or rosacea.
References
- Mosby’s Drug Guide for Nurses (7th edition; Skidmore) 2007.
External links
New Drug Approvals 